Chronic kidney disease (CKD) is one of the fastest-growing major causes of death
internationally. Better treatment of CKD and its complications is crucial to reverse this …

Almost all haemodialysis patients are treated with parenteral iron to compensate for blood
loss and to allow the full therapeutic effect of erythropoiesis-stimulating agents. Iron overload …

Rationale & Objective Intradialytic hypotension and intradialytic hypertension are associated
with morbidity and mortality in hemodialysis (HD). Many factors can contribute to intra-HD …

Parenteral iron is used to restore the body's iron pool before and during erythropoiesis‐
stimulating agent (ESA) therapy; together these agents form the backbone of anemia …

There are data available in the literature on bioelement concentrations in the serum of
various groups of patients; however, very little is known about the serum concentration of …

Patients with end-stage renal disease on dialysis commonly receive intravenous iron to treat
anemia along with erythropoiesis-stimulating agents. While studies of intravenous iron have …

Introduction Patients with chronic kidney disease on hemodialysis (HD) are at high risk of
developing both iron deficiency and iron deficiency anemia (IDA). The administration of …

Este trabajo realiza una actualización sobre el manejo del déficit de hierro en pacientes con
enfermedad renal crónica (ERC), ya sea con o sin anemia. Se revisan las recomendaciones …

The effectiveness of reticulocyte hemoglobin content (CHr) had been reported to detect early
functional iron deficiency especially among Chronic kidney disease (CKD) patients. CHr is …

Background and Objectives: Iron deficiency and anemia characterize patients on chronic
hemodialysis (HD). Available intravenous iron agents, such as ferric gluconate (FG) and …